相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy
Xue Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins
Karson J. Kump et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors
Lulu Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy
Peng-Ju Zhu et al.
DRUG DISCOVERY TODAY (2020)
Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent
Xing Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
Enkhtsetseg Munkhbaatar et al.
NATURE COMMUNICATIONS (2020)
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor
Zoltan Szlavik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Haijiao Zhang et al.
NATURE CANCER (2020)
Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer
Taekyu Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
James W. Papatzimas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models
Xing Lu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity
Zoltan Szlavik et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
Ziqian Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere
Gwenaella Rescourio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
Matthew J. Sale et al.
NATURE COMMUNICATIONS (2019)
Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins
Aline D. de Araujo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Click Chemistry-Based Discovery of [3-Hydroxy-5-(1H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia
Yue Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design
Subrata Shaw et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Proteome-Wide Identification of On- and Off-Targets of Bcl-2 Inhibitors in Native Biological Systems by Using Affinity-Based Probes (AfBPs)
Ziqian Wang et al.
CHEMBIOCHEM (2018)
Targeting Bcl-2 for the treatment of multiple myeloma
Cyrille Touzeau et al.
LEUKEMIA (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel et al.
CANCER DISCOVERY (2018)
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
Patricia Gomez-Bougie et al.
BLOOD (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors
Taekyu Lee et al.
FEBS LETTERS (2017)
Practical Singly and Doubly Electrophilic Aminating Agents: A New, More Sustainable Platform for Carbon-Nitrogen Bond Formation
Padmanabha V. Kattamuri et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors
Jeffrey W. Johannes et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Jingshan Tong et al.
CANCER RESEARCH (2017)
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Jianhui Chang et al.
NATURE MEDICINE (2016)
Deactivation of Mcl-1 by Dual-Function Small-Molecule Inhibitors Targeting the Bcl-2 Homology 3 Domain and Facilitating Mcl-1 Ubiquitination
Ting Song et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2naphthoates as selective inhibitors of the Mcl-1 oncoprotein
Maryanna E. Lanning et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods
Nicholas F. Pelz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Gizem Akcay et al.
NATURE CHEMICAL BIOLOGY (2016)
Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design
Jason P. Burke et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Milan Bruncko et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor
Yu Xiao et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
J. D. Leverson et al.
CELL DEATH & DISEASE (2015)
Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein
Andrew M. Petros et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
STAT3 and MCL-1 associate to cause a mesenchymal epithelial transition
A. P. Renjini et al.
JOURNAL OF CELL SCIENCE (2014)
A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Fardokht Abulwerdi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Silver-Catalyzed Isocyanide-Alkyne Cycloaddition: A General and Practical Method to Oligosubstituted Pyrroles
Jianquan Liu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker
David J. Richard et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach
Zhichao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors
Zhichao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design
Anders Friberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells
Wim Pierson et al.
NATURE IMMUNOLOGY (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
A Competitive Stapled Peptide Screen Identifies a Selective Small Molecule that Overcomes MCL-1-Dependent Leukemia Cell Survival
Nicole A. Cohen et al.
CHEMISTRY & BIOLOGY (2012)
Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation
Kenichiro Doi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Avinash Muppidi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Targeting Mcl-1 for the therapy of cancer
Bridget A. Quinn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) Based Molecules as Potent, Dual Inhibitors of B-Cell Lymphoma 2 (Bcl-2) and Myeloid Cell Leukemia Sequence 1 (Mcl-1): Structure-Based Design and Structure-Activity Relationship Studies
Zhichao Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Mcl-1; the molecular regulation of protein function
Luke W. Thomas et al.
FEBS LETTERS (2010)
Structural Insights into the Design of Small Molecule Inhibitors That Selectively Antagonize Mcl-1
Paul H. Bernardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Michelle L. Stewart et al.
NATURE CHEMICAL BIOLOGY (2010)
Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes
Emiko Fire et al.
PROTEIN SCIENCE (2010)
BID, BIM, and PUMA Are Essential for Activation of the BAX- and BAK-Dependent Cell Death Program
Decheng Ren et al.
SCIENCE (2010)
Mcl-1 is a potential therapeutic target in multiple types of cancer
C. Akgul
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Mcl-1 and Bcl-xL Cooperatively Maintain Integrity of Hepatocytes in Developing and Adult Murine Liver
Hayato Hikita et al.
HEPATOLOGY (2009)
Sequence-based design of alpha/beta-peptide foldamers that mimic BH3 domains
W. Seth Horne et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2008)
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
Chris Pepper et al.
BLOOD (2008)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
KJ Aichberger et al.
BLOOD (2005)
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells
LX Song et al.
CANCER BIOLOGY & THERAPY (2005)
Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream
MR Arkin et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis
M Herrant et al.
ONCOGENE (2004)
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
JT Opferman et al.
NATURE (2003)
Life-or-death decisions by the Bcl-2 protein family
JM Adams et al.
TRENDS IN BIOCHEMICAL SCIENCES (2001)
Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins
RJ Lutz
BIOCHEMICAL SOCIETY TRANSACTIONS (2000)
分享论文
